quinoxalines has been researched along with Lymph Node Metastasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bednova, O; Leyton, JV | 1 |
| Alberts, AR; Iflé, IG; Scholtes, MP; van der Veldt, AAM; Verhagen, PCMS; Zuiverloon, TCM | 1 |
2 review(s) available for quinoxalines and Lymph Node Metastasis
| Article | Year |
|---|---|
Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; B7-H1 Antigen; Camptothecin; Cell Adhesion Molecules; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy; Lymphatic Metastasis; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; Pyrazoles; Quinoxalines; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Renal Cell; Cisplatin; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Kidney Neoplasms; Lymphatic Metastasis; Mutation; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Recurrence; Urinary Bladder Neoplasms | 2021 |